MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia
April 28, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, April 28, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer
March 03, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, March 03, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
January 21, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today its...
Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
January 13, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613® (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting & Expos
December 03, 2019 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
Clinical Oncology Next-generation Sequencing Market Pegged for Robust Expansion of 17.0% CAGR by 2029 - Future Market Insights
May 20, 2019 08:30 ET
|
Future Market Insights
VALLEY COTTAGE, N.Y. , May 20, 2019 (GLOBE NEWSWIRE) -- Next-generation sequencing refers to the identification of the nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology...
Digital Reasoning’s AI Analytics Detects Unsuspected Lung Cancer in Radiology Reports and Augments Clinical Follow-Up
May 16, 2019 14:30 ET
|
Digital Reasoning Systems, Inc.
NASHVILLE, Tenn., May 16, 2019 (GLOBE NEWSWIRE) -- Digital Reasoning, a leader in Artificial Intelligence (AI) that understands human intentions and behaviors, today announced results from its...